Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial

Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study

(2018) O. Nemoto et al.   BRITISH JOURNAL OF DERMATOLOGY

Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study

(2018) Shigetoshi Sano et al.   JOURNAL OF DERMATOLOGY

Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study

(2018) Mamitaro Ohtsuki et al.   JOURNAL OF DERMATOLOGY

Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment

(2018) Tom C. Chan et al.   Therapeutic Advances in Chronic Disease

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

(2018) Kenneth B Gordon et al.   LANCET

Psoriasis and comorbid diseases

(2017) Junko Takeshita et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis

(2017) G. Girolomoni et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

(2017) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)

(2016) Hidehisa Saeki et al.   JOURNAL OF DERMATOLOGY

Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study

(2016) Hideshi Torii et al.   JOURNAL OF DERMATOLOGY

Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study

(2016) Shinichi Imafuku et al.   JOURNAL OF DERMATOLOGY

Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study

(2016) Akihiko Asahina et al.   JOURNAL OF DERMATOLOGY

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

(2015) James G. Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Japanese guidance for use of biologics for psoriasis (the 2013 version)

(2013) Mamitaro Ohtsuki et al.   JOURNAL OF DERMATOLOGY

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

(2011) Tsen-Fang Tsai et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET